​

Cartesian Therapeutics (RNAC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RNAC Stock Forecast

Cartesian Therapeutics (RNAC) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $16.00, with a high of $16.00 and a low of $16.00. This represents a 150.78% increase from the last price of $6.38.

- $7 $14 $21 $28 $35 High: $16 Avg: $16 Low: $16 Last Closed Price: $6.38

RNAC Stock Rating

Cartesian Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 2 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 2 8 Strong Sell Sell Hold Buy Strong Buy

RNAC Price Target Upside V Benchmarks

TypeNameUpside
StockCartesian Therapeutics150.78%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$16.00$16.00
Last Closing Price$6.38$6.38$6.38
Upside/Downside-150.78%150.78%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26171--9
Mar, 26162--9
Feb, 26162--9
Jan, 26162--9
Dec, 25-62--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 09, 2026Cantor Fitzgerald$16.00$9.0277.38%150.78%
Aug 09, 2024Mitchell KapoorH.C. Wainwright$45.00$12.87249.65%605.33%
Jul 03, 2024John NewmanCanaccord Genuity$43.00$15.77172.67%573.98%
May 24, 2024Uy EarMizuho Securities$40.00$25.4657.11%526.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 09, 2026BTIGBuyBuyhold
Dec 19, 2024BTIGBuyinitialise
Sep 04, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024H.C. WainwrightBuyBuyhold
Aug 06, 2024Cowen & Co.Buyinitialise
Jul 02, 2024OppenheimerOutperformPerformdowngrade
Jun 14, 2024OppenheimerOutperformOutperformhold
Jun 04, 2024OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

$-50 $-38 $-26 $-14 $-2 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.74$7.33$-49.76$-2.99$-5.02---
Avg Forecast$-10.59$1.49$-5.25$-5.99$-3.47$-3.69$-5.05$-4.75
High Forecast$-9.46$1.51$-0.58$-5.75$-1.88$-1.61$-3.18$-4.75
Low Forecast$-12.60$1.48$-9.63$-6.22$-4.55$-5.23$-6.24$-4.75
Surprise %-36.36%391.95%847.81%-50.08%44.67%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$85.08M$110.78M$26.00M$38.91M$2.80M---
Avg Forecast$68.16M$96.20M$10.60M$39.74M$6.29M$8.80M$5.00M$34.30M
High Forecast$78.11M$96.85M$13.74M$40.06M$6.29M$8.80M$5.00M$34.30M
Low Forecast$62.56M$95.53M$7.46M$39.56M$6.29M$8.80M$5.00M$34.30M
Surprise %24.83%15.15%145.32%-2.08%-55.50%---

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-25.69M$35.38M$-219.71M$-77.42M$-130.30M---
Avg Forecast$-54.63M$7.72M$-26.39M$-30.95M$-16.61M$-17.68M$-24.35M$-24.57M
High Forecast$-48.79M$7.78M$-3.02M$-29.75M$-9.70M$-8.32M$-16.44M$-24.57M
Low Forecast$-65.00M$7.65M$-49.76M$-32.15M$-23.51M$-27.04M$-32.26M$-24.57M
Surprise %-52.98%358.46%732.55%150.15%684.68%---

RNAC Forecast FAQ

Is Cartesian Therapeutics stock a buy?

Cartesian Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cartesian Therapeutics is a favorable investment for most analysts.

What is Cartesian Therapeutics's price target?

Cartesian Therapeutics's price target, set by 10 Wall Street analysts, averages $16 over the next 12 months. The price target range spans from $16 at the low end to $16 at the high end, suggesting a potential 150.78% change from the previous closing price of $6.38.

How does Cartesian Therapeutics stock forecast compare to its benchmarks?

Cartesian Therapeutics's stock forecast shows a 150.78% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cartesian Therapeutics over the past three months?

  • April 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 11.11% Strong Buy, 66.67% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 11.11% Strong Buy, 66.67% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Cartesian Therapeutics’s EPS forecast?

Cartesian Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.69, marking a -26.49% decrease from the reported $-5.02 in 2025. Estimates for the following years are $-5.05 in 2027, and $-4.75 in 2028.

What is Cartesian Therapeutics’s revenue forecast?

Cartesian Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $8.8M, reflecting a 214.62% increase from the reported $2.8M in 2025. The forecast for 2027 is $5M, and $34.3M for 2028.

What is Cartesian Therapeutics’s net income forecast?

Cartesian Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-17.682M, representing a -86.43% decrease from the reported $-130M in 2025. Projections indicate $-24.352M in 2027, and $-24.572M in 2028.